OMNITROPE 5 MG1.5 ML Israele - inglese - Ministry of Health

omnitrope 5 mg1.5 ml

masrouji co, ltd - somatropin recombinant - solution for injection - somatropin recombinant 5 mg / 1.5 ml - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (height sds<2.5 and parenteral adjusted height sds < -1) in short children born sga (sga - small for gestational age i.e. born small in relation to the length of the fetus development) with a birth weight and/or length < 2 sd who failed to show catch up growth (hv sds < 0 during the last year) by 4 years of age or later. prader willi syndrome (pws) for improvement of growth and body composition. adults: for adults who have suffered from growth-hormone deficiency since childhood. for adults who have acquired growth hormone deficiency due to a pituitary pathology causing hypopituitarism.

VYVANSE 50 MG Israele - inglese - Ministry of Health

vyvanse 50 mg

medison pharma ltd - lisdexamfetamine dimesylate - capsules - lisdexamfetamine dimesylate 50 mg - lisdexamfetamine - vyvanse is a central nervous system (cns) stimulant indicated for the treatment of attention deficit hyperactivity disorder (adhd) in patients ages 6 years and above.vyvanse is indicated for the treatment of moderate to severe binge eating disorder (bed) for patient over 18 years.limitation of use:vyvanse is not indicated or recommended for weight loss. use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. the safety and effectiveness of vyvanse for the treatment of obesity have not been established

CARTIA Israele - inglese - Ministry of Health

cartia

padagis israel agencies ltd, israel - acetylsalicylic acid - tablets enteric coated - acetylsalicylic acid 100 mg - acetylsalicylic acid - acetylsalicylic acid - the primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.

STAY SAFE BALANCE 1.5% glucose 1.25 mmolL calcium peritoneal dialysis solution bag Malesia - inglese - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

stay safe balance 1.5% glucose 1.25 mmoll calcium peritoneal dialysis solution bag

fresenius medical care malaysia sdn bhd - calcium chloride dihydrate ph. eur.; magnesium chloride hexahydrate pheur; glucose monohydrate, ph eur; sodium chloride (nacl); sodium lactate (50%) -

STAY SAFE BALANCE 2.3% glucose 1.25 mmolL calcium peritoneal dialysis solution bag Malesia - inglese - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

stay safe balance 2.3% glucose 1.25 mmoll calcium peritoneal dialysis solution bag

fresenius medical care malaysia sdn bhd - magnesium chloride hexahydrate pheur; sodium lactate solution (50%); glucose monohydrate, ph eur; sodium chloride (nacl); calcium chloride dihydrate ph. eur. -